Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Nivolumab in Advanced Carcinoid Tumors
NCT04197310Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib, nivolumab in Carcinoid Tumor (CT), sponsored by Dana-Farber Cancer Institute. Started Dec 2019; status: completed.
02
Drugs
cabozantinibnivolumab
03
Conditions
Carcinoid Tumor (CT)
Beyond the preview
Go deeper on NCT04197310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04197310.